Currently browsing tag

seen-at-their

Roche receives blood cancer drug blow after Gazyva trial fails to meet endpoint

Swiss drugmaker Roche said trials showed its new blood cancer drug Gazyva failed to deliver significant improvements over an older medicine in people with an aggressive type of blood cancer, a blow in its fight against competition from biosimilars. Gazyva did not significantly reduce the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma, over current drug Rituxan in a phase III GOYA study, Roche said on Monday. Diffuse large B-cell lymphoma is the most common form of non-Hodgkin's lymphoma.

Pfizer’s quit-smoking drug not linked to depression or heart risks

By Kate Kelland LONDON (Reuters) – Pfizer's stop-smoking drug Chantix does not raise risks of heart attack or depression, contrary to previous reports, and should be recommended to more smokers wanting to quit, scientists said on Monday. In a study tracking 150,000 smokers in England for 6 months, researchers found that patients who took Chantix, known generically as varenicline and marketed as Champix in Europe, were no more likely to suffer a heart attack than those using nicotine replacement therapy or another quit-smoking drug.